The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study.

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2024-10-21 DOI:10.1111/dom.16016

Yiling Lou, Yulin Xie, Qingqing Jiang, Shen Huang, Xiaohan Wang, Linlin Wang, Hengchang Wang, Shiyi Cao

{"title":"The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study.","authors":"Yiling Lou, Yulin Xie, Qingqing Jiang, Shen Huang, Xiaohan Wang, Linlin Wang, Hengchang Wang, Shiyi Cao","doi":"10.1111/dom.16016","DOIUrl":null,"url":null,"abstract":"Aim: To investigate the effect of sarcopenic obesity on the progression of glycaemic status in middle-aged and older adults without diabetes.Materials and methods: This research involved 4637 participants without diabetes from the China Health and Retirement Longitudinal Study 2011-2015. Sarcopenic obesity at baseline was evaluated based on the Asian Working Group for Sarcopenia 2019 criteria. According to the American Diabetes Association criteria, we used fasting plasma glucose and glycated haemoglobin to define glycaemic status. Cox proportional hazard models were applied to obtain adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).Results: The mean age of included participants was 58.98 ± 8.82 years, and 45.35% were men. During 18,497 person-years of follow-up, 1743 (37.59%) cases with glycaemic status progression were identified. Compared with participants without sarcopenia and obesity, participants with sarcopenic obesity, but not sarcopenia only or obesity only, exhibited a higher risk of progression from normoglycaemia to diabetes (HR = 2.11; 95% CI: 1.10-4.04). Moreover, participants with sarcopenic obesity (HR = 1.65; 95% CI: 1.04-2.63), sarcopenia only (HR = 1.78; 95% CI: 1.11-2.86), or obesity only (HR = 2.00; 95% CI: 1.29-3.12) had increased the risk of progression from prediabetes to diabetes.Conclusions: The effect of sarcopenic obesity on the progression of glycaemic status based on fasting plasma glucose and glycated haemoglobin may be more pronounced than that of sarcopenia only or obesity only.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16016","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate the effect of sarcopenic obesity on the progression of glycaemic status in middle-aged and older adults without diabetes.

Materials and methods: This research involved 4637 participants without diabetes from the China Health and Retirement Longitudinal Study 2011-2015. Sarcopenic obesity at baseline was evaluated based on the Asian Working Group for Sarcopenia 2019 criteria. According to the American Diabetes Association criteria, we used fasting plasma glucose and glycated haemoglobin to define glycaemic status. Cox proportional hazard models were applied to obtain adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: The mean age of included participants was 58.98 ± 8.82 years, and 45.35% were men. During 18,497 person-years of follow-up, 1743 (37.59%) cases with glycaemic status progression were identified. Compared with participants without sarcopenia and obesity, participants with sarcopenic obesity, but not sarcopenia only or obesity only, exhibited a higher risk of progression from normoglycaemia to diabetes (HR = 2.11; 95% CI: 1.10-4.04). Moreover, participants with sarcopenic obesity (HR = 1.65; 95% CI: 1.04-2.63), sarcopenia only (HR = 1.78; 95% CI: 1.11-2.86), or obesity only (HR = 2.00; 95% CI: 1.29-3.12) had increased the risk of progression from prediabetes to diabetes.

Conclusions: The effect of sarcopenic obesity on the progression of glycaemic status based on fasting plasma glucose and glycated haemoglobin may be more pronounced than that of sarcopenia only or obesity only.

查看原文本刊更多论文

基于空腹血浆葡萄糖和糖化血红蛋白的肌肉疏松性肥胖对血糖状况的影响：一项前瞻性队列研究。

目的：探讨肌肉疏松性肥胖对无糖尿病的中老年人血糖状态进展的影响：本研究涉及 2011-2015 年中国健康与退休纵向研究中的 4637 名无糖尿病参与者。基线时的肌营养不良性肥胖根据亚洲肌营养不良工作组 2019 年标准进行评估。根据美国糖尿病协会的标准，我们使用空腹血浆葡萄糖和糖化血红蛋白来定义血糖状况。采用 Cox 比例危险模型得出调整后的危险比（HRs）和 95% 置信区间（CIs）：研究对象的平均年龄为 58.98 ± 8.82 岁，45.35% 为男性。在 18497 人年的随访中，发现了 1743 例（37.59%）血糖状况恶化的病例。与没有患有肌肉疏松症和肥胖症的参与者相比，患有肌肉疏松性肥胖症的参与者从正常血糖状态发展为糖尿病的风险更高（HR = 2.11；95% CI：1.10-4.04）。此外，患有肌肉疏松性肥胖症（HR = 1.65；95% CI：1.04-2.63）、仅患有肌肉疏松症（HR = 1.78；95% CI：1.11-2.86）或仅患有肥胖症（HR = 2.00；95% CI：1.29-3.12）的参与者从糖尿病前期发展为糖尿病的风险更高：结论：与单纯肌肉疏松症或单纯肥胖症相比，肌肉疏松性肥胖症对以空腹血浆葡萄糖和糖化血红蛋白为基础的血糖状况恶化的影响可能更为明显。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.